Please use this identifier to cite or link to this item:
Title: Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
Authors: PICANCO-CASTRO, VirginiaBONAMINO, Martin HernanRAMOS, Rodrigo NalioGUERINO-CUNHA, Renato L.OLIVEIRA, Theo Gremen M.REGO, Eduardo M.
Citation: HEMATOLOGY TRANSFUSION AND CELL THERAPY, v.43, suppl.2, p.S54-S63, 2021
Abstract: Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended period of preclinical evaluation that demonstrated unprecedented efficacy in this difficult-to-treat patient population. This review article outlines the main preclinical evaluations needed for CAR T cell product development. (C) 2021 Published by Elsevier Espana, S.L.U. on behalf of Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/31
LIM/31 - Laboratório de Genética e Hematologia Molecular

Files in This Item:
File Description SizeFormat 
art_PICANCO-CASTRO_Associacao_Brasileira_de_Hematologia_Hemoterapia_e_Terapia_Celular_2021.PDFpublishedVersion (English)880.06 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.